Oral Cancer Disparities in Low‑ and Middle‑Income Countries: A Global Health Equity Perspective on Prevention, Early Detection, and Treatment Access

Survival and functional outcomes

Five‑year survival underscores the equity divide where HICs report ~68–85% overall survival (with >90% for stage I–II), whereas LMICs often achieve only ~25–45% and some subregions fall below 20% [15]. Stage at presentation explains that much of the gap such as 55–70% is in early‑stage detection in HICs versus 15–35% in LMICs, but differences persist even after adjusting for stage, reflecting systemic deficits in surgical, radiation, pathology, and supportive care [16, 17]. Post‑treatment function and quality of life (speech, swallowing, and nutrition) are poorer in LMICs because the reconstructive options such as speech therapy and multidisciplinary rehabilitation are less available [18].

Tobacco (combusted and smokeless), areca, and alcohol

Tobacco remains the dominant risk factor. Over 80% of the world’s 1.3 billion tobacco users live in LMICs, where product diversity complicates regulation and cessation [19]. In addition to manufactured cigarettes, LMIC markets feature bidis and kreteks, water pipe products, and an array of smokeless forms, such as gutka, khaini, and zarda often mixed with areca nut and slaked lime, creating an alkaline milieu that augments mucosal carcinogen absorption [20, 21]. Toxicant profiles can exceed those of cigarettes; tobacco‑specific nitrosamines in smokeless mixtures are sometimes several‑fold higher; and sustained mucosal contact magnifies the exposure [22]. The summary of representative studies is presented in Table 1.

Alcohol is a potent cofactor. Many LMICs have parallel markets for home‑distilled or informally sold beverages with variable ethanol content and contaminants (e.g., methanol and acetaldehyde) that raise carcinogenic potential beyond commercial products [23]. Tobacco–alcohol synergy is multiplicative; cousers have ~10–20× higher oral cancer risk than abstainers [24]. Cultural norms varied from ceremonial use to perceived medicinal value which shape acceptability and complicate policy management, requiring locally tailored strategies [25].

Environmental, occupational, and waterborne exposures

Structural exposures elevate baseline risk. Ambient air pollution exceeds WHO guidelines for ~92% of LMIC populations, while indoor biomass combustion exposes ~2.6 billion people to carcinogens such as benzopyrene and formaldehyde at concentrations far above outdoor urban levels in HICs [26, 27]. Occupational exposures such as pesticides in agriculture and solvents and dusts in industry are common under weak regulatory enforcement and limited personal protective equipment [28]. Chronic ingestion of toxic metals, notably arsenic in groundwater, affects over 140 million people globally, with concentrations in some regions far surpassing safety thresholds [29].

Nutrition, micronutrients, and food safety

Dietary insufficiency and food insecurity shape susceptibility. Diets low in fruits and vegetables (and therefore antioxidants and fiber) but high in processed and preserved foods reduce mucosal resilience and immune surveillance [30]. Micronutrient deficiencies including folate, vitamin B₁₂, and iron are highly prevalent (20–70% in some LMIC cohorts) and can impair DNA repair, methylation balance, and host defense [31]. Traditional preservation methods (smoking, salting, and fermentation) can generate nitrosamines and polycyclic aromatic hydrocarbons; aflatoxin contamination in staple foods remains common in tropical climates without adequate storage [32, 33].

Primary‑care readiness and access

Primary‑care platforms are the linchpin for prevention and early detection but remain under‑resourced. Health‑worker density averages ~2.3 per 1,000 in LMICs versus ~12.8 in HICs, limiting capacity for community outreach, risk counseling, and routine oral examination [34]. Oral‑health content in medical and nursing curricula is minimal (often ≤8 hours), leaving frontline clinicians unprepared for systematic oral screening or potential malignant disorder (PMD) management [35]. Facility assessments indicate that 60–80% of primary centers lack basic equipment for oral inspection; digital photography that would facilitate remote consultation is uncommon [36]. Distance and cost are major barriers, with rural populations traveling 25–50 km to reach facilities and transportation frequently costing a day’s wages [37].

Specialist, diagnostic, and therapeutic capacity

Downstream services are thinly distributed. The density of oral and maxillofacial surgeons averages ~0.1 per 100,000 in LMICs (vs. ~2.5 in HICs), and entire countries may lack training programs [38]. Pathologist availability is ~10× lower than in HICs; biopsy turnaround frequently spans 4–12 weeks, delaying definitive management [39]. Radiotherapy capacity meets only ~35% of need overall; several regions lack radiotherapy unit within 1,000 km, producing wait lists that render some tumors inoperable by the time therapy begins [40]. Quality assurance systems are limited, with external quality control in fewer than one‑third of laboratories and routine outcome auditing in fewer than one‑fifth of cancer centers [41].

Referral pathways, records, and patient support

Referral clarity and care coordination remain weak. An estimated 70–85% of primary providers lack explicit referral criteria for suspicious lesions; patients often receive incomplete instructions, and back‑referrals are rare [42]. Paper records dominate in 80–90% of systems, and loss of information across levels of care is common; electronic records cover less than 10% in many LMICs versus ~85–95% in HICs [43]. Patient navigation is effective for adherence in HICs, which is available in less than 5% of LMIC cancer centers where treatment abandonment rates of 25–45% have been reported [44]. Collectively, these data underscore how structural inequities, not only behavioral risks, drive outcome disparities (Table 2).

Comprehensive tobacco control and alcohol policy

Beyond summarizing known disparities, this review synthesizes actionable levers for governments, health systems, and international partners to accelerate equity in oral cancer outcomes. WHO framework convention on tobacco control aligned strategies, such as taxation, smoke‑free laws, advertising bans, pictorial warnings, and cessation support, remain the most powerful levers for primary prevention [45]. Modeling and empirical evaluations suggest that robust implementation can reduce oral cancer incidence by 20–40% within 10–15 years. Excise taxes are especially potent; a 10% price increase typically reduces consumption by 4–8%, with the largest effects among youth and low‑income groups; however, policies must anticipate substitution and illicit trade dynamics to sustain gains [46]. Smoke‑free legislation reduces exposure and changes norms but depends on enforcement capacity; mass‑media campaigns with culturally tailored messaging raise quit attempts and deter initiation at low cost per disability adjusted life year (DALY) averted [47, 48].

Human papillomavirus (HPV) vaccination

HPV contribute substantially to oropharyngeal cancers in younger cohorts, and expanding vaccination offers a dual benefit alongside cervical cancer prevention. Coverage in most LMICs remains less than 50%, but school‑based delivery can achieve 80–95% uptake when paired with community engagement and health‑worker training. Rwanda’s program reached 93% coverage by integrating schools, primary care, and communication strategies [49, 50]. Economic analyses consistently show cost‑effectiveness ($100–$500 per DALY averted), particularly with pooled procurement mechanisms [51].

Nutrition and food safety

Population strategies to increase fruit and vegetable intake through subsidies, supply‑chain improvements, and social marketing are associated with 40–60% risk reductions in observational syntheses [52]. In high‑risk groups with documented deficiencies, targeted supplementation (e.g., folate and B‑complex) has slowed PMD progression by ~30–50% in trials [53]. Food‑safety interventions to reduce aflatoxin‑improved drying/storage, biocontrol, and regulatory standards have reduced contamination by 50–80% in program settings and brought cross‑cancer benefits [54].

Screening and triage pathways

Visual inspection by trained oral health‑care providers is a pragmatic foundation for early detection in high‑prevalence settings. With standardized protocols and supportive supervision, programs achieve approximately 60–85% sensitivity and 85–95% specificity, with cost‑effectiveness ratios around $200–$800 per DALY averted [55]. Complementary evidence shows that 20–40 hours of hands‑on training with refreshers sustains skill retention (>80% at one year) and that external quality assurance improves sensitivity by 15–25% [56, 57]. Adjunctive technologies (e.g., vital staining and autofluorescence) may raise sensitivity in some contexts, but their incremental value depends on cost, maintenance, and operator skill [58]. Digital innovations can extend reach. Smartphone‑enabled tele‑mentoring and store‑and‑forward imaging have demonstrated 80–90% diagnostic concordance with in‑person specialist assessment when images and metadata follow standardized protocols [59]. Early artificial intelligence algorithms approach specialist‑level accuracy in controlled datasets; the next step is prospective validation, bias assessment and lesion types, and embedding within referral pathways with human oversight [60].

Surgical services and task sharing

Even basic surgical capacity is insufficient in many LMICs. Workforce analyses suggest that LMICs collectively possess only ~20–40% of the specialized personnel needed for current demand, with training pipelines graduating fewer than 50 specialists per year across many countries [45]. Infrastructure deficits such as operating rooms, anesthesia, and ICU beds limit case complexity, and equipment shortages affect 70–90% of facilities attempting cancer surgery [46]. Perioperative mortality for major oral cancer resections is approximately 8–15% in LMIC settings versus 1–3% in high‑resource centers, where international‑standard resources and training exist and outcomes converge, demonstrating feasibility [47]. Pragmatic task sharing, including training general surgeons for early‑stage resections under specialist oversight with clear referral thresholds, has shown acceptable results and can be scaled with tele‑mentoring and standardized protocols [48].

Radiotherapy access and regional cooperation

Radiotherapy is a critical bottleneck. Meeting current needs would require 5,000–8,000 additional machines (approximately $15–$25 billion capital investment), as existing capacity serves only 35–45% of indicated patients [49]. Regional centers of excellence and cross‑border referral networks can partially close gaps, and pooled procurement and shared maintenance have reduced per‑patient costs by 40–60% and improved uptime in West African pilots [50]. Tele‑radiotherapy with remote planning and quality assurance under standardized protocols has achieved acceptable plan quality (85–95% meeting benchmarks) when linked with on‑site technical support [51].

Financial protection

Cancer care imposes severe financial strain. In many LMICs, direct medical costs for oral cancer equal 2–5 times of annual household income; 80–95% of affected families experience catastrophic health expenditure [52]. Indirect costs such as transport, lodging, and wage loss often match or exceed medical bills, especially in rural households where travel to tertiary centers is prolonged [53, 54]. Insurance coverage is sparse (15–35%) and frequently limited by co‑pays and benefit caps [55]. Countries that expanded social health insurance (e.g., Thailand and Rwanda) cut out‑of‑pocket spending by 60–80% and increased treatment completion [56]. Targeted budget lines for cancer equivalent to 0.1–0.3% of national health expenditure have produced measurable improvements in access where sustained [57].

WHO frameworks and “best buys”

The WHO Global Action Plan for noncommunicable diseases (NCDs) embeds oral cancer control within broader prevention, and the WHO “Best Buy” package highlights tobacco and alcohol policies as highly cost‑effective levers [58, 59]. Modeling suggests that comprehensive implementation could avert 25–40% of oral cancer cases at less than $150 per DALY averted, an unusually favorable ratio for cancer control. The WHO Package of Essential NCD Interventions (PEN) provides a standardized, primary‑care adaptable oral screening protocol that has proven feasible when combined with training and quality assurance [60].

Implementation research and capacity building

Persistent gaps concern delivery science rather than discovery. Priorities include (i) prospective evaluation of scaled visual screening with digital decision support and tele‑consultation, (ii) hybrid effectiveness–implementation trials of culturally tailored cessation and alcohol‑reduction packages, (iii) pragmatic trials of task sharing for early oral cancer surgery with tele‑mentoring, and (iv) cost and equity evaluations of regional radiotherapy networks. North–South and South–South partnerships can accelerate technology transfer with open‑source digital tools, simplified treatment guidelines, and shared training curricula, while building local bioengineering and biomedical technician capacity.

This review is limited by variability in regional data completeness and heterogeneity in oral cancer definitions across registries. The narrative nature of the synthesis carries a risk of selection and publication bias. Despite these limitations, triangulation of multiple international data sources provides a robust approximation of global oral cancer disparities.